Santhera Pharmaceuticals Holding AG - Company Profile
Powered by 
All the sales intelligence you need on Santhera Pharmaceuticals Holding AG in one solution.
- Save hours of research time with a comprehensive
Sales Intelligence Solution.
- Understand how Santhera Pharmaceuticals Holding AG fits into your total
addressable market and Ideal Customer Profile.
- Gain competitive edge with triggers that tell you
when and how to engage with Santhera Pharmaceuticals Holding AG.
Get in touch about GlobalData Company reports
Contact the team or request a demo to find out how our data can drive your business forward
Business Description
Santhera Pharmaceuticals Holding AG (Santhera) is a specialty pharmaceutical company that primarily focuses on the development and commercialization of innovative medicines for patients living with rare and other diseases with high unmet medical needs. The company is particularly focused on the development of treatments for neuromuscular diseases that currently lack treatment options, such as Duchenne muscular dystrophy (DMD). The company classifies its operations into one reportable operational segment: the development and commercialization of products for the treatment of neuromuscular and pulmonary diseases.
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.
R&D Overview
Santhera is currently focusing its research and development initiatives on creating treatment options for rare diseases, specifically neuromuscular diseases. These include Duchenne muscular dystrophy (DMD), a common and severe type of muscular degeneration that results in progressive muscle weakness from an early age, and Becker muscular dystrophy (BMD), a progressive muscle wasting disease similar to DMD but typically milder. The company incurred research and development expenses of CHF26.5 million in FY2024, which as a percentage of revenue stood at 67.7% and grew 41.7% YoY.
Still looking?
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Explorer
Access more premium companies when you subscribe to Explorer